Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy

Journal of Gastroenterology

Volumn 41, Issue 8, 2006, Pages 785-790

  Rokuhara, Akinori ^a   Matsumoto, Akihiro ^a   Tanaka, Eiji ^a   Umemura, Takeji ^a   Yoshizawa, Kaname ^a   Kimura, Tatsuji ^b   Maki, Noboru ^b   Kiyosawa, Kendo ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FUJIREBIO INC   (Japan)

Author keywords

cccDNA; Chronic hepatitis B; Sucrose gradient analysis; Viral load; Viral replication

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENTARY DNA; DEOXYRIBONUCLEASE I; HEPATITIS B CORE ANTIGEN; LAMIVUDINE; RIBONUCLEASE; SUCROSE; VIRUS DNA; VIRUS RNA;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA SYNTHESIS; DRUG MONITORING; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; SUCROSE DENSITY GRADIENT CENTRIFUGATION; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS PARTICLE;

ADULT; AGED; CENTRIFUGATION, DENSITY GRADIENT; DNA, VIRAL; FEMALE; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VIRAL LOAD;

EID: 33749031000     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-006-1856-4     Document Type: Article

References (25)

1. WC Maddrey 2000 Hepatitis B: An important public health issue J Med Virol 61 362-6 10861647 1:STN:280:DC%2BD3cvgsFChsA%3D%3D 10.1002/ 1096-9071(200007)61:3<362::AID-JMV14>3.0.CO;2-I
2. RP Beasley LY Hwang CC Lin CS Chien 1981 Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22-707 men in Taiwan Lancet 2 1129-33 6118576 1:STN:280:Bi2D2sblslA%3D 10.1016/S0140-6736(81)90585-7
3. YF Liaw JJ Sung WC Chow G Farrell CZ Lee H Yuen 2004 Lamivudine for patients with chronic hepatitis B and advanced liver disease N Engl J Med 351 1521-31 15470215 1:CAS:528:DC%2BD2cXot1Kls7w%3D 10.1056/ NEJMoa033364
4. A Matsumoto E Tanaka A Rokuhara K Kiyosawa H Kumada M Omata 2005 Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients Hepatol Res 32 173-84 16024289 1:CAS:528:DC%2BD2MXmvVCmsbo%3D 10.1016/ j.hepres.2005.02.006
5. JL Dienstag RD Goldin EJ Heathcote HW Hann M Woessner SL Stephenson 2003 Histological outcome during long-term lamivudine therapy Gastroenterology 124 105-17 12512035 1:CAS:528:DC%2BD3sXot1antQ%3D%3D 10.1053/gast.2003.50013
6. JL Dienstag RP Perrillo ER Schiff M Bartholomew C Vicary M Rubin 1995 A preliminary trial of lamivudine for chronic hepatitis B infection N Engl J Med 333 1657-61 7477217 1:CAS:528:DyaK28XkvFyqtw%3D%3D 10.1056/ NEJM199512213332501
7. SL Doong CH Tsai RF Schinazi DC Liotta YC Cheng 1991 Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues Proc Natl Acad Sci U S A 88 8495-9 1656445 1:CAS:528:DyaK3MXms12qurk%3D 10.1073/pnas.88.19.8495
8. CL Lai RN Chien NW Leung TT Chang R Guan DI Tai 1998 A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group N Engl J Med 339 61-8 9654535 1:CAS:528:DyaK1cXkvVSqtbY%3D 10.1056/ NEJM199807093390201
9. WM Lee 1997 Hepatitis B virus infection N Engl J Med 337 1733-45 9392700 1:STN:280:DyaK1c%2FktFyjtA%3D%3D 10.1056/NEJM199712113372406
10. WS Mason MS Halpern JM England G Seal J Egan L Coates 1983 Experimental transmission of duck hepatitis B virus Virology 131 375-84 6659368 1:CAS:528:DyaL2cXmsFCksg%3D%3D 10.1016/0042-6822(83)90505-6
11. J Summers WS Mason 1982 Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate Cell 29 403-15 6180831 1:CAS:528:DyaL38Xks1Ojurg%3D 10.1016/0092-8674(82)90157-X
12. JS Tuttleman C Pourcel J Summers 1986 Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells Cell 47 451-60 3768961 1:CAS:528:DyaL2sXhtlynug%3D%3D 10.1016/ 0092-8674(86)90602-1
13. JJ Sung ML Wong S Bowden CT Liew AY Hui VW Wong 2005 Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy Gastroenterology 128 1890-7 15940624 1:CAS:528:DC%2BD2MXlvFKlsLc%3D 10.1053/j.gastro.2005.03.009
14. T Kimura A Rokuhara Y Sakamoto S Yagi E Tanaka K Kiyosawa 2002 Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load J Clin Microbiol 40 439-45 11825954 1:CAS:528:DC%2BD38XhvFGktbk%3D 10.1128/JCM.40.2.439-445.2002
15. A Rokuhara E Tanaka A Matsumoto T Kimura T Yamaura K Orii 2003 Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen: A marker distinct from viral DNA for monitoring lamivudine treatment J Viral Hepat 10 324-30 12823601 1:STN:280:DC%2BD3s3ps1yhsQ%3D%3D 10.1046/j.1365-2893.2003.00437.x
16. E Tanaka A Matsumoto F Suzuki M Kobayashi M Mizokami Y Tanaka 2006 Measurement of hepatitis B virus core-related antigen is valuable for identifying patients who are at low risk of lamivudine resistance Liver Int 26 90-6 16420514 1:CAS:528:DC%2BD28XisFCmu7s%3D 10.1111/ j.1478-3231.2005.01200.x
17. M Mizokami T Nakano E Orito Y Tanaka H Sakugawa M Mukaide 1999 Hepatitis B virus genotype assignment using restriction fragment length polymorphism patterns FEBS Lett 450 66-71 10350059 1:CAS:528:DyaK1MXivFegsbg%3D 10.1016/S0014-5793(99)00471-8
18. T Kimura A Rokuhara A Matsumoto S Yagi E Tanaka K Kiyosawa 2003 New enzyme immunoassay for detection of hepatitis B virus core antigen (HBcAg) and relation between levels of HBcAg and HBV DNA J Clin Microbiol 41 1901-6 12734224 1:CAS:528:DC%2BD3sXktlGrsrc%3D 10.1128/ JCM.41.5.1901-1906.2003
19. T Gerelsaikhan JE Tavis V Bruss 1996 Hepatitis B virus nucleocapsid envelopment does not occur without genomic DNA synthesis J Virol 70 4269-74 8676448 1:CAS:528:DyaK28XjsFyhu74%3D
20. Q Su SF Wang TE Chang R Breitkreutz H Hennig K Takegoshi 2001 Circulating hepatitis B virus nucleic acids in chronic infection: representation of differently polyadenylated viral transcripts during progression to nonreplicative stages Clin Cancer Res 7 2005-15 11448918 1:CAS:528:DC%2BD3MXlslalurY%3D
21. W Zhang HJ Hacker M Tokus T Bock CH Schroder 2003 Patterns of circulating hepatitis B virus serum nucleic acids during lamivudine therapy J Med Virol 71 24-30 12858405 1:CAS:528:DC%2BD3sXmslOrtLw%3D 10.1002/jmv.10464
22. B Werle-Lapostolle S Bowden S Locarnini K Wursthorn J Petersen G Lau 2004 Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy Gastroenterology 126 1750-8 15188170 1:CAS:528:DC%2BD2cXlsFaqs78%3D 10.1053/j.gastro.2004.03.018
23. YF Liaw RN Chien CT Yeh SL Tsai CM Chu 1999 Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy Hepatology 30 567-72 10421670 1:CAS:528:DyaK1MXlt1ajsLg%3D 10.1002/hep.510300221
24. F Suzuki A Tsubota Y Arase Y Suzuki N Akuta T Hosaka 2003 Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan Intervirology 46 182-9 12867757 1:CAS:528:DC%2BD3sXntFyqsbg%3D 10.1159/000071460
25. B Zollner P Schafer HH Feucht M Schroter J Petersen R Laufs 2001 Correlation of hepatitis B virus load with loss of e antigen and emerging drug-resistant variants during lamivudine therapy J Med Virol 65 659-63 11745928 1:CAS:528:DC%2BD3MXovFSgurw%3D 10.1002/jmv.2087